<DOC>
	<DOCNO>NCT02501330</DOCNO>
	<brief_summary>The objective surveillance collect information 1. adverse drug reaction expect LPD ( unknown adverse drug reaction ) 2. incidence adverse drug reaction surveillance 3. factor consider affect safety and/or efficacy drug .</brief_summary>
	<brief_title>Safety And Efficacy Of Bosutinib</brief_title>
	<detailed_description>The patient register central registration system .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Chronic myelogenous leukemia patient resistant intolerant prior treatment experience drug Patients history hypersensitivity Women may possibly pregnant become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug use investigation Japan</keyword>
</DOC>